FIT: Post-acute Multicomponent Frailty Intervention

Sponsor
Hebrew SeniorLife (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05906446
Collaborator
(none)
100
1
12

Study Details

Study Description

Brief Summary

The goal is to test feasibility of a frailty intervention, including exercises and nutritional supplementation.

Condition or Disease Intervention/Treatment Phase
  • Other: Multicomponent (Exercise + Protein Supplementation)
N/A

Detailed Description

The frailty intervention includes frequent short exercise sessions incorporating balance, resistance training, and walking to accommodate diminished endurance, with synergistic protein and nutritional supplementation, delivered on top of usual care in the post-acute Skilled Nursing Facility (SNF) setting. There is no control group.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Feasibility of a Multicomponent Frailty Intervention During Post-acute Rehabilitation in Skilled Nursing Facilities
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Regular exercise sessions incorporating balance, resistance training, and walking to accommodate diminished endurance, with synergistic protein and nutritional supplementation

Other: Multicomponent (Exercise + Protein Supplementation)
Exercises selected from a pre-specified list, reassessed weekly Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week) Participants will also be offered a protein supplement within 30 min of exercise. Sessions will be supervised

Outcome Measures

Primary Outcome Measures

  1. Feasibility of the Intervention [Estimated average <1 month]

    Feasibility will be determined by assessing 1) the proportion of eligible patients enrolled, 2) the proportion of participants adherent to the intervention, and 3) the proportion lost to follow-up after three weeks of intervention. Feasibility is defined as at least 70% of eligible patients are successfully enrolled and complete the full intervention (receiving ≥80% of sessions). Range: 0-100% (higher values indicate higher feasibility).

Secondary Outcome Measures

  1. Gait Speed [Discharge (on average between 2-3 weeks)]

    Walking speed measured in m/s

  2. Grip Strength [Discharge (on average at 2-3 weeks)]

    Dominant Hand Grip Strength measured in Kg (higher values indicate better performance)

  3. The Patient Reported Outcomes Measurement Information System (PROMIS Global Health v1.2) [Discharge (on average at 2-3 weeks)]

    The PROMIS Scale v1.2 - Global Health (also referred to as PROMIS-10) is a ten-item patient reported measure of physical, mental and social health. Items query general health, quality of life, physical health, mental health, satisfaction with discretionary social activities, carrying out every day physical activities, pain, fatigue, satisfaction with social roles, and emotional problems (Hays et al., 2009). Physical Health (physical health, physical function, pain, and fatigue items) and Mental Health (quality of life, mental health, satisfaction with discretionary social activities, and emotional problem items) (Hays et al., 2009). T scores for both Physical and Mental Health scales.

  4. Modified Barthel Index [Discharge (on average at 2-3 weeks)]

    Assessment of functional disability based on 10 activities of daily life (ADLs). Range 0-10 with high values indicating better performance.

  5. Adherence to exercise [Entire study period (on average over 2-3 weeks)]

    Proportion of sessions with ≥15 minutes of exercise during the intervention period Range: 0-100% (higher values indicate better adherence)

  6. Adherence to supplementation [Entire study period (on average over 2-3 weeks)]

    Proportion of oral nutritional supplement consumed over the total number of supplements during the intervention period per self-report Range: 0-100% (higher values indicate better adherence)

Other Outcome Measures

  1. Length of stay [Entire study period (on average over 2-3 weeks)]

    Length of admission to SNF

  2. Hospital readmission [Entire study period (on average over 2-3 weeks)]

    Proportion of participants who are readmitted to the hospital during SNF stay

  3. Community Discharge [Entire study period (on average over 2-3 weeks)]

    Proportion of participants who are discharged to the community from SNF stay

  4. Falls [Entire study period (on average over 2-3 weeks)]

    Proportion of participants who experience a fall, as documented in the medical record, during SNF stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Community-dwelling before hospitalization

  • Age ≥ 65 years

  • Admitted to SNF directly from inpatient hospitalization

  • English speaking

  • Mild Frailty or worse, as measured by a Clinical Frailty Scale

Exclusion Criteria:
  • Discharged from Emergency Department

  • Non-community discharge plan on admission (e.g. plan to discharge to hospice)

  • Nothing per oral (NPO) dietary status

  • Presence of any feeding tube

  • Chronic kidney disease stage IV or worse

  • Clinician refusal

  • Inability or refusal to consume intervention products (e.g. allergies to protein supplement)

  • Inability to consent to study procedures

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hebrew SeniorLife

Investigators

  • Principal Investigator: Sandra Shi, MD MPH, Hebrew SeniorLife

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sandra Shi, Instructor of Medicine, Hebrew SeniorLife
ClinicalTrials.gov Identifier:
NCT05906446
Other Study ID Numbers:
  • Pro00068129
First Posted:
Jun 15, 2023
Last Update Posted:
Jun 23, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2023